ALK and non-small cell lung carcinoma: A phase III eXalt3 trial demonstrated that ensartinib (X-396) monotherapy, as a first-line treatment for patients with ALK-p advanced NSCLC, is better than crizotinib monotherapy in prolonging PFS (HR 0.51, 95% CI: 0.35–0.72) [41].